Saxenda Injection Tutorials on TikTok: What Doctors Get Right and Wrong

TikTok has become a surprisingly common place to find health information. For people prescribed weight-management medications, short videos can make complicated instructions feel much easier to understand. A clinician demonstrating how to use a medication pen can also be genuinely helpful—especially when the video focuses on practical technique.

But there is an important distinction between showing someone how a medication is administered and explaining who should take it, how treatment should be adjusted, and whether it is appropriate for a particular patient.

A recent TikTok tutorial from Dr. Monica Peres Oikeh demonstrates how to use a Saxenda pen, including preparing the pen, selecting a dose, injecting subcutaneously, and completing the injection. Much of the technique described in the video is consistent with established Saxenda guidance. However, one important part of the eligibility information is incomplete.

This article breaks down what the tutorial gets right, what it leaves out, and why patients should treat social-media demonstrations as educational supplements—not replacements for a prescribing clinician's advice.

What the TikTok Saxenda Tutorial Actually Shows

The video is presented as a practical demonstration for people who have already been prescribed Saxenda.

The creator walks viewers through several aspects of using the injection pen, including:

• Preparing the pen

• Attaching the needle

• Selecting the prescribed dose

• Injecting the medication under the skin

• Holding the pen in position before removal

• Disposing of the needle after use

• Discussing storage

• Explaining the daily injection schedule

She also identifies the starting dose as 0.6 mg and explains that Saxenda is administered subcutaneously.

That framing is important. The video is primarily a technique tutorial, rather than a comprehensive explanation of who should receive liraglutide or how a patient's treatment should be managed.

What the Video Gets Right

Much of the basic information in the tutorial aligns with established Saxenda prescribing guidance.

The 0.6 mg starting dose

The video correctly identifies 0.6 mg as the starting dose.

However, that does not mean 0.6 mg is the long-term maintenance dose. Saxenda treatment uses gradual dose escalation, with increases of 0.6 mg at weekly intervals until the recommended maintenance dose is reached.

This gradual approach is important because gastrointestinal adverse effects are common with GLP-1 receptor agonists.

Patients should follow the dosing schedule provided by their prescribing clinician rather than attempting to accelerate the process based on information from social media.

Subcutaneous administration

The tutorial correctly explains that Saxenda is administered subcutaneously.

Subcutaneous medication is delivered into the tissue beneath the skin rather than directly into a vein or muscle.

The technique demonstrated in the video is therefore consistent with the medication's intended route of administration.

The abdomen is an approved injection site

The video demonstrates injection into the abdomen, which is an appropriate site.

However, the abdomen is not the only approved location. Saxenda can also be administered subcutaneously in the thigh or upper arm.

Patients should follow the injection-site instructions provided with their medication and by their healthcare professional.

Holding the pen before removing it

The tutorial tells viewers to count before removing the pen after administering the dose.

The source material identifies this as a count to six. The purpose is to help ensure that the intended dose has been delivered before the needle is removed.

This isn't merely a random trick included to make the tutorial more detailed. It reflects standard pen-injection technique.

Using a new needle

The advice to discard the needle after each injection is also an important safety point.

Reusing needles can create hygiene and dosing concerns. Following the manufacturer's instructions for needle disposal and using a new needle for each injection helps maintain appropriate injection practices.

The Biggest Problem: The BMI Eligibility Information

The most significant issue identified in the video concerns the BMI threshold.

The tutorial reportedly describes a BMI above 35 as the relevant threshold for Saxenda.

That description is incomplete.

According to the source material, Saxenda's eligibility criteria include a BMI of 30 or above, or a BMI of 27 or above when accompanied by at least one weight-related health condition.

Examples of weight-related conditions can include conditions such as type 2 diabetes, hypertension, or dyslipidaemia.

That distinction matters because someone who hears only "BMI over 35" could incorrectly conclude that they are not eligible to discuss Saxenda with a clinician.

Why eligibility should not be reduced to one number

BMI is only one part of a prescribing decision.

A healthcare professional needs to consider the individual's medical history, existing conditions, medications, treatment goals, contraindications, and other relevant factors.

A social-media video cannot perform that assessment.

That is why an eligibility statement should be treated as general educational information rather than as a personal prescription decision.

Saxenda Is Not the Same as Other Popular GLP-1 Medications

Another important point that can easily get lost in social-media discussions is that not all GLP-1 medications are interchangeable.

Saxenda contains liraglutide.

Other well-known medications in the same broader treatment category contain different active ingredients, such as semaglutide or tirzepatide.

These medications can have different:

• Dosing schedules

• Approved indications

• Dose-escalation protocols

• Clinical outcomes

• Side-effect profiles

• Contraindications

• Prescribing requirements

For that reason, information from a video about one GLP-1 medication should not automatically be applied to another.

A tutorial showing how to use a Saxenda pen is specifically about liraglutide and its delivery device.

Why Dose Escalation Matters

One of the most important pieces of information missing from many short-form medication videos is the complete treatment schedule.

Saxenda is not normally started at the full maintenance dose.

The source material describes a gradual progression beginning with 0.6 mg daily and increasing by 0.6 mg increments each week until reaching the 3 mg maintenance dose.

The purpose of gradual escalation is primarily to improve tolerability.

Gastrointestinal side effects

GLP-1 receptor agonists can cause gastrointestinal symptoms, particularly during dose escalation.

These can include symptoms such as:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Abdominal discomfort

Increasing the dose faster than instructed can make tolerability more difficult.

A patient should therefore never use a TikTok video to determine when to increase a prescribed dose.

The prescribing instructions from the patient's healthcare professional should take priority.

What Clinical Evidence Says About Liraglutide

The source material references the SCALE Obesity and Prediabetes trial published in the New England Journal of Medicine.

In that study, liraglutide 3 mg was associated with greater average weight loss than placebo over 56 weeks.

The source reports approximately 8% average body-weight loss with liraglutide compared with 2.6% with placebo.

These results provide useful context, but clinical trial averages should not be interpreted as a guarantee of what an individual patient will experience.

Weight-management outcomes vary from person to person.

Factors such as adherence, underlying health conditions, treatment duration, lifestyle, tolerability, and individual response can all influence results.

What a TikTok Tutorial Cannot Tell You

Even an accurate injection demonstration has major limitations.

It cannot determine whether you should take Saxenda

A social-media creator cannot evaluate your complete medical history through a short video.

It cannot identify every contraindication

Prescription medications can have contraindications and precautions that require a full medical assessment.

It cannot review medication interactions

A clinician needs to know what other prescription medicines, over-the-counter products, and supplements a patient is taking before making an appropriate prescribing decision.

It cannot monitor your response

A video cannot determine whether a medication is working appropriately or whether adverse effects require medical attention.

It cannot replace follow-up care

Weight-management treatment may require ongoing assessment rather than a single prescription and injection demonstration.

Storage Information Matters Too

The source material notes that the creator discusses refrigerated storage.

Proper storage is important for maintaining medication quality.

Patients should follow the storage instructions supplied with their specific Saxenda product and should not assume that general advice from another GLP-1 video applies to every medication.

When in doubt, the product's official prescribing information and pharmacist guidance are more reliable than social-media comments.

How to Evaluate GLP-1 Advice on TikTok

Not every health video on TikTok is inaccurate. The challenge is determining which parts are supported by reliable evidence.

A useful approach is to ask five questions.

1. Is the creator a qualified healthcare professional?

Professional credentials can provide useful context, but credentials alone do not make every statement in a short video complete.

Look for references to official prescribing information, regulatory agencies, or peer-reviewed research.

3. Is the information specific to the medication?

Do not assume that instructions for liraglutide automatically apply to semaglutide or tirzepatide.

4. Does the video explain limitations?

Good medical communication should distinguish general information from individualized treatment advice.

5. Does the information match your prescription?

Your own prescription instructions should take priority over a generic social-media tutorial.

A Better Way to Use Injection Tutorials

If you have already been prescribed Saxenda, an instructional video can be useful as a visual reminder of technique.

However, it should be used alongside—not instead of—your healthcare professional's instructions.

A sensible process is:

1. Review the official medication instructions.

2. Follow the dose prescribed by your clinician.

3. Watch a reputable demonstration if you need a visual explanation.

4. Ask your pharmacist or healthcare professional about anything unclear.

5. Never change your dose based solely on social-media advice.

6. Seek professional advice if you experience concerning symptoms.

This approach lets you benefit from the convenience of online education without treating a short video as a personalized treatment plan.

Common Mistakes People Make With Social-Media Health Advice

Mistaking a demonstration for a prescription

A creator can demonstrate injection technique without knowing whether the viewer should use the medication.

Applying one GLP-1's instructions to another

Different medications can have different doses, schedules, devices, and approved uses.

Ignoring the full eligibility criteria

Reducing eligibility to one BMI number can create unnecessary confusion.

Skipping professional follow-up

Even when the injection technique is straightforward, medication management still requires clinical oversight.

Assuming trial results guarantee personal results

Clinical trial averages describe groups of participants. They do not predict exactly what will happen to one individual.

Frequently Asked Questions

Is Saxenda a GLP-1 medication?

Yes. Saxenda contains liraglutide, a GLP-1 receptor agonist used for weight management in appropriate patients.

What is the starting dose discussed in the tutorial?

The source material identifies 0.6 mg as the starting dose. Treatment then uses gradual escalation under the prescribing instructions.

Where can Saxenda be injected?

The source material identifies the abdomen, thigh, and upper arm as approved subcutaneous injection sites.

Is Saxenda the same as semaglutide?

No. Saxenda contains liraglutide, while semaglutide is a different active ingredient. They belong to the same broader medication class but are not the same drug.

Can a TikTok video determine whether someone qualifies for Saxenda?

No. Eligibility requires an individualized clinical assessment.

Is TikTok a reliable source for medication instructions?

TikTok can provide useful educational demonstrations, but short videos may omit important eligibility, safety, dosing, and monitoring information. Medication instructions should be confirmed using official prescribing information and guidance from a qualified healthcare professional.

The Bottom Line

The Saxenda tutorial reviewed here gets many of the injection mechanics right. The 0.6 mg starting dose, subcutaneous administration, abdominal injection site, daily schedule, storage discussion, needle disposal, and post-injection technique are broadly consistent with the information described in established Saxenda guidance.

The most important weakness is the simplified BMI eligibility statement. Presenting a BMI above 35 as the relevant threshold leaves out people who may meet the stated criteria at lower BMI levels when a weight-related comorbidity is present.

That illustrates the larger lesson with health content on TikTok: a video can demonstrate one part of a treatment correctly while still leaving out information that matters clinically.

Use social-media tutorials as visual education, not as a substitute for a medical assessment. Before starting Saxenda or changing how it is used, confirm the medication, dose, eligibility, and injection instructions with the healthcare professional who prescribed it.

Medical disclaimer: This article is for educational purposes only and is not a substitute for individualized medical advice. Medication eligibility, dosing, and treatment decisions should be discussed with a qualified healthcare professional.